OCUPHIRE PHARMA INC (OCUP)

Company Profile

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. The company is headquartered in Farmington Hills, Michigan and currently employs 9 full-time employees. The company went IPO on 2004-11-30. The firm is focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its pipeline includes two small molecule product candidates targeting several of such indications. Nyxol Eye Drops (Nyxol) is a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity. Nyxol can potentially be used across multiple indications such as treatment of pharmacologically induced mydriasis (RM), presbyopia (age-related blurry near vision) and dim light or night vision disturbances (DLD) (halos, glares and starbursts). Its product candidate, APX3330, is a twice-a-day oral tablet designed to target multiple pathways relevant to retinal and choroidal (the vascular layer of the eye) diseases. The firm has also in-licensed APX2009 and APX2014, which are second-generation product candidates and analogs of APX3330.

Company Info

OCUPHIRE PHARMA INC

37000 Grand River Ave., Suite 120

Farmington Hills MICHIGAN 48335

P: 12486819815

CEO: Mina Sooch

Employees: 9

Website: https://www.ocuphire.com/